Chemocentryx Inc. (CCXI)
NASDAQ:CCXI

ChemoCentryx Stock Analysis & Ratings

CCXI Stock Chart & Stats

Day’s Range$21.61 - $23.28
52-Week Range$9.53 - $42.16
Previous Close$22.05
Volume1.94M
Average Volume (3M)1.46M
Market Cap$1.62B
P/E Ratio-11.4
Beta1.95
Next EarningsAug 08, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score10
EPS (TTM)-2.00


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CCXI FAQ

What was ChemoCentryx’s price range in the past 12 months?
ChemoCentryx lowest stock price was $9.53 and its highest was $42.16 in the past 12 months.
    What is ChemoCentryx’s market cap?
    ChemoCentryx’s market cap is $1.62B.
      What is ChemoCentryx’s price target?
      The average price target for ChemoCentryx is $76.25. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $106.00 ,the lowest forecast is $34.00. The average price target represents 234.58% Increase from the current price of $22.79.
        What do analysts say about ChemoCentryx?
        ChemoCentryx’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
          When is ChemoCentryx’s upcoming earnings report date?
          ChemoCentryx’s upcoming earnings report date is Aug 08, 2022 which is in 79 days.
            How were ChemoCentryx’s earnings last quarter?
            ChemoCentryx released its earnings results on May 05, 2022. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.309 by -$0.241.
              Is ChemoCentryx overvalued?
              According to Wall Street analysts ChemoCentryx’s price is currently Undervalued.
                Does ChemoCentryx pay dividends?
                ChemoCentryx does not currently pay dividends.
                What is ChemoCentryx’s EPS estimate?
                ChemoCentryx’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does ChemoCentryx have?
                ChemoCentryx has 71,190,000 shares outstanding.
                  What happened to ChemoCentryx’s price movement after its last earnings report?
                  ChemoCentryx reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.309. Following the earnings report the stock price went up 11.125%.
                    Which hedge fund is a major shareholder of ChemoCentryx?
                    Among the largest hedge funds holding ChemoCentryx’s share is Perceptive Advisors LLC. It holds ChemoCentryx’s shares valued at 41M.

                      ---

                      ChemoCentryx Stock Analysis

                      Smart Score
                      10
                      Outperform
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $76.25
                      ▲(234.58% Upside)
                      Strong Buy
                      The ChemoCentryx stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Chemocentryx Inc.

                      ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      AbbVie
                      Biogen
                      Bristol Myers
                      Pfizer
                      Johnson & Johnson

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis